Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Vanda strongly disputes the FDA’s reasoning
Subscribe To Our Newsletter & Stay Updated
